References
Rosenberg AS. Effects of protein aggregates. An immunologic perspective. AAPS J. 2006;8:E501-E507.
Chi EY, Weickman J, Carpenter JF, Manning MC, Randolph TW. Heterogeneous nucleation-controlled particulate formation of recombinant human platelet-activating factor acetylhydrolase in pharmaceutical formulation. J Pharm Sci. 2005;94:256–274.
Cromwell MEM, Hilario E, Jacobson F. Protein aggregation and bioprocessing. AAPS J. 2006;8:E572-E579.
Philo JS. Is any measurement method optimal for all aggregate sizes and types? AAPS J. 2006;8:E564-E571.
Berkowitz SA. Role of analytical ultracentrifugation in assessing the aggregation of protein biopharmaceuticals. AAPS J. 2006;8:E590-E605.
Schuck P. Size-distribution analysis of macromolecules by sedimentation velocity ultracentrifugation and lamm equation modeling. Biophysical Journal. 2000;78:1606–1619.
Liu J, Andya JD, Shire SJ. A critical review of analytical ultracentrifugation and field flow fractionation methods for measuring protein aggregation. AAPS J. 2006;8:E580-E589.
Shire SJ. 2005 AAPS Biotechnology Conference Open Forum on Aggregation of Protein Therapeutics-Panel Discussion, June 5–8, 2005, San Francisco, CA. AAPS J. 2006;8:E644-E654.
Author information
Authors and Affiliations
Additional information
Published: December 1, 2006
Rights and permissions
About this article
Cite this article
Shire, S.J., Cromwell, M. & Liu, J. Concluding summary: Proceedings of the AAPS Biotec Open Forum on “Aggregation of Protein Therapeutics”. AAPS J 8, 82 (2006). https://doi.org/10.1208/aapsj080482
Received:
Accepted:
DOI: https://doi.org/10.1208/aapsj080482